Qiming U.S. Ventures Management, LLC

Qiming U.S. Ventures Management, LLC is the U.S. registered investment management entity associated with Qiming Venture Partners’ healthcare-focused platform. Based in Seattle, Washington, the firm manages venture capital funds that invest primarily in early- and growth-stage life sciences companies in the United States and, selectively, Europe. Its mandate concentrates on innovative therapeutics, medical technologies, and healthcare services, extending Qiming’s broader pan-Asian venture franchise into Western markets. The firm operates as an exempt reporting adviser and institutional investment manager, overseeing private limited partnerships for institutional investors and qualified purchasers. It files quarterly Form 13F with the U.S. Securities and Exchange Commission under CIK #0001909617. These filings disclose Qiming U.S. Ventures’ reportable long positions in U.S.-listed equities and certain equity-linked instruments—typically stakes in portfolio companies that have gone public or in selected public healthcare names related to its core themes. The bulk of its capital resides in private companies and non-reportable instruments, so the 13F data represent the public tail of a predominantly private venture strategy. On an advanced 13F analytics platform, the firm’s full 13F history can be transformed into a manager-specific Historical Track Record, normalized to a user-defined starting notional, providing allocators with a holdings-based view of the capital trajectory implied by its disclosed public positions.

Qiming U.S. Ventures Management, LLC pursues a specialist venture capital strategy focused on healthcare and life sciences innovation. The investment team targets companies with differentiated science or technology and clear pathways to meaningful clinical and commercial impact. Core areas include: - Biopharmaceuticals (novel therapeutics and platform technologies) - Medical devices and diagnostics - Life science tools and enabling technologies - Select digital health and tech-enabled healthcare services The firm typically invests at Series A through later private rounds, with a long-duration horizon that spans preclinical or early clinical development through pivotal trials, regulatory milestones, and commercialization. Governance-oriented involvement—board representation, strategic guidance, and syndicate leadership—is a defining feature of the strategy. Public-market exposure arises when portfolio companies complete IPOs, direct listings, or SPAC transactions, and Qiming U.S. Ventures retains equity stakes post-listing. The resulting 13F Portfolio Composition therefore tends to feature: - Concentrated positions in a limited number of U.S.-listed biotech and medtech issuers originating from the private portfolio - Occasional holdings in other listed healthcare companies that complement existing thematic exposure or offer liquidity management flexibility - Minimal or no use of broad-market ETFs, reflecting the firm’s company-building rather than index-oriented mandate Turnover in the public sleeve is generally low. Positions are often held beyond lock-up expiries to capture additional value as clinical data accumulate and commercial execution unfolds, with distribution and exit decisions guided by valuation discipline, risk management, and fund-life considerations rather than short-horizon trading. For users running a Portfolio Simulator or Backtesting Service, it is important to interpret these holdings as the public expression of long-running venture theses rather than as a standalone trading strategy.

Qiming U.S. Ventures Management, LLC represents the U.S. healthcare venturing arm of a major cross-border venture capital platform, with a mandate focused on high-impact life sciences innovation. Its 13F filings under CIK #0001909617 offer a narrow but insightful window into how the firm manages and seasons public stakes in former private portfolio companies and selected listed healthcare names, rather than depicting a diversified, benchmark-aware equity fund. For allocators and researchers, the most informative lens is holdings-based analysis. Examining the evolution of 13F Portfolio Composition across the firm’s 13F history reveals how concentrated the U.S.-listed sleeve has been at different points, which subsectors (therapeutics, devices, tools, digital health) dominate at various stages of the cycle, and how quickly Qiming U.S. Ventures distributes or trims positions after key milestones. Using Performance Backtests Online to convert these filings into a normalized Historical Track Record, and overlaying estimates of the portfolio’s Volatility Profile and implied Sharpe Ratio, enables a structured assessment of the disclosed book’s compounding behavior through multiple biotech and funding cycles. The central diagnostic question for further due diligence is how dynamically Qiming U.S. Ventures adjusts its mix of public holdings—by subsector, development stage, and single-name concentration—as regimes shift between risk-on periods of abundant biotech capital, more selective environments with higher funding costs, and phases of regulatory or clinical disappointment, and how clearly those shifts are reflected in the capital path implied by its reported 13F holdings.

The risk profile implied by Qiming U.S. Ventures’ disclosed holdings is that of a concentrated, sector-specialist venture investor in healthcare. Biotech and early-stage medical technology equities are inherently volatile, driven by binary clinical readouts, regulatory decisions, financing conditions, and shifting sentiment toward specific modalities or therapeutic areas. Key risk drivers in the public sleeve include: - Clinical and regulatory binary events that can cause large discontinuous moves in individual stocks - Funding and dilution risk in pre- or early-commercial companies dependent on capital markets access - Sector and thematic concentration in healthcare, amplifying sensitivity to changes in sentiment toward life sciences as an asset class - Liquidity risk in small- and mid-cap issuers, particularly during periods of market stress When the reported positions are reconstructed into a long-only time series, the resulting Volatility Profile typically exceeds that of broad equity benchmarks, with pronounced swings around major data releases and sector drawdowns. Because Form 13F does not capture any hedging via options, indices, or cross-asset positions, the synthetic replication should be viewed as an upper bound on directional equity risk in the disclosed sleeve rather than a complete picture of fund-level exposure. Despite elevated variability, the objective of the strategy is to translate scientific and clinical insight into durable value creation in a subset of portfolio companies. On a normalized notional, an analytics engine can estimate an implied Sharpe Ratio for the 13F-replicated book, providing a quantitative gauge of how effectively the visible holdings have historically converted this volatility into risk-adjusted outcomes, while recognizing that the primary benchmark for a specialist healthcare venture investor is not necessarily a broad index.